Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma
About the study
The purpose of this study is to evaluate the efficacy and safety of JCAR017 in participants with aggressive B-cell non-Hodgkin lymphoma (B-NHL)
Who can take part
You may be eligible to participate in the study if you meet the following criteria:
INCLUSION CRITERIA
Inclusion Criteria:
- Histological confirmation of diagnosis at last relapse
- Adequate organ function
- Adequate vascular access for leukapheresis procedure
EXCLUSION CRITERIA
Exclusion Criteria:
- Prior history of malignancies, other than aggressive relapsed/refractory Non-Hodgkin Lymphoma, unless the participant has been in remission for ≥ 2 years with the exception of non-invasive malignancies
- Received previous CD19-targeted therapy
- Progressive vascular tumor invasion, thrombosis, or embolism
Other protocol-defined inclusion/exclusion criteria apply
Study Locations
Enter your ZIP code/Postal code/PIN code to locate study sites near you:
How to Apply
Contact the study center to learn if this study is a good match for you.
Study’s details
Contition
Lymphoma, Non-Hodgkin
Age (in years)
18+
Phase
Phase 2
Participants needed
112
Est. Completion Date
Dec 15, 2023
Treatment type
Interventional
Sponsor
Celgene
ClinicalTrials.gov identifier
NCT03484702
Study number
JCAR017-BCM-001
Understanding Clinical Trials
Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?